Table 4 Subgroup analysis and exploration of heterogeneity in CD22 CAR-T clinical trials
Patients with available data | Overall response rate | Complete response rate | negative Minimal residual disease | Cytokine release syndrome |  ≥ Grade 3 cytokine release syndrome | Neurotoxicity |  ≥ Grade 3 neurotoxicity | Relapse rate | CD22 dim/negative relapse rate |
|---|---|---|---|---|---|---|---|---|---|
Age Group | |||||||||
 Children (N = 114) | 76% (68–83) | 74% (65–81) | - | 87% (80–92) | 6% (3–12) | 28% (21–37) | - | 36% (18–54) | 16% (0–32) |
 Adult (N = 37) | 75% (59–87) | 57% (41–72) | - | 84% (68–93) | 5% (1–19) | 11% (4–25) | - | 6% (0–20) | 3% (0–9) |
 p value | 0.94 | 0.05* | - | 0.6 | 0.9 | 0.04* | - | 0.01** | 0.14 |
Bone marrow involvement (B-ALL) | |||||||||
 High burden (N = 98) | 74% (65–82) | 63% (43–83) | 66% (55–75) | 86% (78–92) | 7% (3–14) | 25% (17–34) | 1% (0–7) | 23% (6–58) | 8% (1–46) |
 Low burden (N = 25) | 81% (66–96) | 76% (59–93) | 68% (48–83) | 88% (69–96) | 4% (1–24) | 32% (17–52) | 4% (1–24) | 40% (23–60) | 12% (4–31) |
 p value | 0.22 | 0.54 | 0.82 | 0.81 | 0.6 | 0.46 | 0.32 | 0.37 | 0.73 |
Disease | |||||||||
 B-ALL (N = 133) | 76% (69–83) | 72% (65–80) | - | 87% (82–93) | 4% (1–8) | 20% (8–32) | 1% (0–3) | 31% (13–49) | 11% (0–23) |
 B cell lymphoma (N = 28) | 86% (73–99) | 64% (47–82) | - | 74% (19–100) | 4% (0–12) | 10% (0–28) | 0% (0–6) | 8% (0–19) | 4% (0–12) |
 p value | 0.19 | 0.41 | - |  < 0.01** | 0.87 | 0.36 | 0.75 | 0.04* | 0.35 |
Prior CD19 CAR-T therapy | |||||||||
 Yes (N = 67) | 75% (65–87) | 73% (62–86) | 45% (16–74) | 76% (62–91) | 9% (3–30) | 0% (0–6) | 0% (0–6) | 19% (0–46) | 24% (9–66) |
 No (N = 15) | 76% (58–100) | 79% (58–100) | 62% (22–100) | 83% (62–100) | 13% (3–58) | 0% (0–6) | 0% (0–6) | 29% (5–52) | 20% (7–60) |
 p value | 0.76 | 0.64 | 0.5 | 0.59 | 0.72 | 1 | 1 | 0.59 | 0.55 |